The state of Texas currently has 6 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
NCT04856982
Recruiting
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Austin Neuromuscular Center, Austin, Texas
Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Register for Updates
Clinical Procedures to Support Research in ALS
NCT03489278
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of Texas San Antonio Health Science Center, San Antonio, Texas
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Nantz National Alzheimer Center Houston, Houston, Texas +1 locations
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
Regulatory T Cells for Amyotrophic Lateral Sclerosis
NCT05695521
Recruiting
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
02/16/2024
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
NCT04244630
Recruiting
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of... Read More
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
03/25/2022
Locations: VA North Texas Health Care System, Dallas, Texas
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers
NCT05279755
Recruiting
This trial is a Phase 1a/1b, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of prosetin administered to healthy adult subjects.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2022
Locations: Worldwide Clinical Trials Early Phase Services, San Antonio, Texas
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates